

More Industry Management Joins ViewRay

ViewRay is pleased to announce that two industry veterans from MDS Nordion, the world's leader in gamma-ray radiotherapy, have joined the Company. Both of these radiotherapy experienced managers will play key roles in advancing the development of the Renaissance System 1000™.

As ViewRay's new Vice President of Product Development, Rob Perrins will be responsible for overall system engineering. Mr. Perrins has more than 20 years experience in product and process development, product manufacture and quality systems, including ISO 9001 and US FDA's current Good Manufacturing Practices (cGMP).

Peter D'Amico is ViewRay's new Director of Market development and will be immediately focusing on Canadian membership for the *IGRT Alliance* and, additionally, Renaissance™ System customer design requirements. Mr. D'Amico was formerly Product Manager for the MDS Nordion External Beam Therapy Product Line, Regional Sales Manager, and International Sales Specialist for Teletherapy Products. *IGRT Leadership Alliance* membership includes, among other benefits, a substantial Renaissance™ price reduction, research funding, and the advantage of becoming one of the first, exclusive North American research sites.

"ViewRay is all about gamma-ray radiation and real-time imaging. To be able to bring aboard management thoroughly experienced in this arena is a real management coup," said Russell Donda, ViewRay CEO. "Our entire focus is on methodically, but rapidly, developing and bringing to market a revolution in radiotherapy. These are the guys to help make this happen."

Monumental engineering challenges have confounded the development of radiotherapy technology that would enable something as simple as imaging the patient during radiation treatment. The state-of-the-art, radiation therapy devices sold today are grossly incompatible with the only technology capable of real-time volumetric imaging—

magnetic resonance imaging or *MRI*. Conversely, the potential alternative to MRI—real-time x-ray or CT scanning—while likewise presenting serious technical challenges is, more importantly, a source of dangerous, patient radiation in excess of that from the treatment itself.

The Renaissance™ circumvents these heretofore, insurmountable engineering and safety challenges and promises to be the world's first radiation therapy device that will allow real-time volumetric MRI *simultaneous* with beam-on radiation delivery. For the first time in the history of radiation therapy, the treating physician will know precisely where the dose is going and if its actually hitting the intended target.

ViewRay has licensed its patent pending technology from the University of Florida and is solely dedicated to its development and commercialization.

Contact: Russ Donda, C.E.O. ViewRay Inc., 374-4005; rsdonda@viewray.com